New Two-Drug combo tested for Hard-to-Treat blood cancers
NCT ID NCT06350318
Summary
This study is testing whether combining two existing drugs—rituximab and zanubrutinib—is safe and effective for people with untreated slow-growing B-cell lymphomas. It will enroll 43 adults with either follicular lymphoma or marginal zone lymphoma who need systemic treatment. Researchers will measure how well the combination shrinks tumors and controls the disease over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.